AstraZeneca (AZN) said Friday that the US Food and Drug Administration has approved its experimental drug, calquence, combined with bendamustine and rituximab, for the treatment of certain adult patients with previously untreated mantle cell lymphoma.
The company said the approval was based on phase III results that showed calquence plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy.
The drugmaker also said the approval converts calquence's earlier accelerated approval, granted by the FDA in October 2017, into full approval for adult mantle cell lymphoma patients.
AZN shares were 0.3% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.